Zhengjun Lin

Dr. Zhengjun Lin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2023 in Cancer Letters
Verified
Journal Article
Closed access
ZLZhengjun Lin
Zhengjun Lin
YJYuqiao Ji
Yuqiao Ji
JZJian Zhou
Jian Zhou
GLGuoqing Li
Guoqing Li
YWYanlin Wu
Yanlin Wu
TLTang Liu
Tang Liu

1 April 2021 in Cancer Letters
Verified
Journal Article
Closed access
ZLZhengjun Lin
Zhengjun Lin
XXXubin Xie
Xubin Xie
SLShiyao Lu
Shiyao Lu
TLTang Liu
Tang Liu

22 July 2024 in The FASEB Journal
Verified
Journal Article
Open access
ZZZhiming Zhang
Zhiming Zhang
BLBinfeng Liu
Binfeng Liu
ZLZhengjun Lin
Zhengjun Lin
LMLin Mei
Lin Mei
RCRuiqi Chen
Ruiqi Chen
ZLZhihong Li
Zhihong Li
Secreted phosphoprotein 1 (SPP1), also known as osteopontin, is a phosphorylated protein. High SPP1 expression levels have been detected in multiple cancers and are associated with poor prognosis and reduced survival rates. However, only a few pan‐cancer analyses have targeted SPP1. We conducted a comprehensive analysis using multiple public databases, including TIMER and TCGA, to investigate the expression levels of SPP1 in 33 different tumor types. In addition, we verified the effect of SPP1 on osteosarcoma. To assess the impact of SPP1 on patient outcomes, we employed univariate Cox regression and Kaplan–Meier survival analyses to analyze overall survival (OS), disease‐specific survival (DSS), and progression‐free interval (PFI) in these tumor patients. We also explored SPP1 gene alterations in various tumor tissues using cBioPortal. We then examined the relationship between SPP1 and clinical characteristics, TME, immune regulatory genes, immune checkpoints, TMB, and MSI using R language. In addition, we used GSEA to investigate the molecular mechanisms underlying the role of SPP1. Bioinformatics analysis indicated that SPP1 was upregulated in 17 tumors. Overexpression of SPP1 results in poor OS, DSS, and PFI in CESC, ESCA, GBM, LGG, LIHC, PAAD, PRAD, and skin cutaneous melanoma. SPP1 expression was positively associated with immunocyte infiltration, immune regulatory genes, immune checkpoints, TMB, MSI, and drug sensitivity in certain cancers. We found that high expression of SPP1 in osteosarcoma was related to drug resistance and metastasis and further demonstrated that SPP1 can stimulate osteosarcoma cell proliferation via CCND1 by activating the PI3K/Akt pathway. These findings strongly suggest that SPP1 is a potential prognostic marker and novel target for cancer immunotherapy.

1 November 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZLZhengjun Lin
Zhengjun Lin
SLShiyao Lu
Shiyao Lu
XXXubin Xie
Xubin Xie
XYXuyang Yi
Xuyang Yi
HHHe Huang
He Huang
Pancreatic cancer is the fourth-leading cause of cancer-related deaths and is expected to be the second-leading cause of cancer-related deaths in Europe and the United States by 2030. The high fatality rate of pancreatic cancer is ascribed to untimely diagnosis, early metastasis and limited responses to both chemotherapy and radiotherapy. Although gemcitabine, 5-fluorouracil and some other drugs can profoundly improve patient prognosis, most pancreatic cancer patients eventually develop drug resistance, leading to poor clinical outcomes. The underlying mechanisms of pancreatic cancer drug resistance are complicated and inconclusive. Interestingly, accumulating evidence has demonstrated that different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), play a crucial role in pancreatic cancer resistance to chemotherapy reagents. In this paper, we systematically summarize the molecular mechanism underlying the influence of ncRNAs on the generation and development of drug resistance in pancreatic cancer and discuss the potential role of ncRNAs as prognostic markers and new therapeutic targets for pancreatic cancer.

18 March 2025 in Cancer Research
Verified
Journal Article
Closed access
JZJing Zeng
Jing Zeng
ZLZhengjun Lin
Zhengjun Lin
XZXianghong Zhang
Xianghong Zhang
TZTao Zheng
Tao Zheng
HXHaodong Xu
Haodong Xu
TLTang Liu
Tang Liu
Neoantigens represent a class of antigens within tumor microenvironments that arise from diverse somatic mutations and aberrations specific to tumorigenesis, holding substantial promise for advancing tumor immunotherapy. However, only a subset of neoantigens effectively elicits antitumor immune responses, and the specific neoantigens recognized by individual T-cell receptors (TCR) remain incompletely characterized. Therefore, substantial research has focused on screening immunogenic neoantigens, mainly through their major histocompatibility complex (MHC) presentation and TCR recognition specificity. Given the resource intensiveness and inefficiency of experimental validation, predictive models based on artificial intelligence (AI) have gradually become mainstream methods to discover immunogenic neoantigens. In this article, we provide a comprehensive summary of current AI methodologies for predicting neoantigens, with a particular focus on their capability to model peptide–MHC (pMHC) and pMHC–TCR binding. Furthermore, a thorough benchmarking analysis was conducted to assess the performance of antigen presentation predictors for scoring the immunogenicity of neoantigens. AI models have potential applications in the treatment of clinical diseases although several limitations must first be overcome to realize their full potential. Anticipated advancements in data accessibility, algorithmic refinement, platform enhancement, and comprehensive validation of immune processes are poised to enhance the precision and utility of neoantigen prediction methodologies. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.

1 December 2020 in Life Sciences
Verified
Journal Article
Closed access
ZLZhengjun Lin
Zhengjun Lin
ZFZhihua Fan
Zhihua Fan
XZXianghong Zhang
Xianghong Zhang
JWJia Wan
Jia Wan
TLTang Liu
Tang Liu